Amyolateral sclerosis (Lou Gehrig’s Disease) is
Post# of 148168
(Total Views: 719)
Posted On: 08/21/2020 4:30:58 PM
Amyolateral sclerosis (Lou Gehrig’s Disease) is a prime indication for Leronlimab. RANTES is key modulator of auto-immune neurodegeneration.
I have seen a number of popular news articles lately on amyotrophic lateral sclerosis, and knowing that it is an autoimmune disorder, briefly explored the available research.
It appears that ALS is strongly correlated to elevated RANTES. As there are not currently any effective therapies for ALS, this is an indication for which a Leronlimab trial should be conducted.
I have known many wonderful people taken far to early by Cancer, HIV and Alzheimer's, both early and late onset. The tragedy of ALS, with its seemingly inexplicable appearance in the prime of life, ranks at the top of my list of heartbreaks.
I know we small and not so small shareholders likely don't get to choose the target of the next clinical trial. I guess I'll put it on my Christmas list and send it in December.
I can believe in miracles. Leronlimab has arrived.
Read More: https://investorshangout.com/post/view?id=586...z6VmQzpHJJ
A couple of good links strongly implicating RANTES in ALS:
https://jneuroinflammation.biomedcentral.com/...018-1135-3
https://pubmed.ncbi.nlm.nih.gov/17852013/
We are on the brink of ending many previously untreatable diseases. Truly we are all blessed that Leronlimab is emerging from the shadows to save the lives of millions.
A bit of a repost, but I still hope this is quickly added to the indications being explored by Cytodyn.
I have seen a number of popular news articles lately on amyotrophic lateral sclerosis, and knowing that it is an autoimmune disorder, briefly explored the available research.
It appears that ALS is strongly correlated to elevated RANTES. As there are not currently any effective therapies for ALS, this is an indication for which a Leronlimab trial should be conducted.
I have known many wonderful people taken far to early by Cancer, HIV and Alzheimer's, both early and late onset. The tragedy of ALS, with its seemingly inexplicable appearance in the prime of life, ranks at the top of my list of heartbreaks.
I know we small and not so small shareholders likely don't get to choose the target of the next clinical trial. I guess I'll put it on my Christmas list and send it in December.
I can believe in miracles. Leronlimab has arrived.
Read More: https://investorshangout.com/post/view?id=586...z6VmQzpHJJ
A couple of good links strongly implicating RANTES in ALS:
https://jneuroinflammation.biomedcentral.com/...018-1135-3
https://pubmed.ncbi.nlm.nih.gov/17852013/
We are on the brink of ending many previously untreatable diseases. Truly we are all blessed that Leronlimab is emerging from the shadows to save the lives of millions.
A bit of a repost, but I still hope this is quickly added to the indications being explored by Cytodyn.
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼